Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Amphastar director Petersen sells $21.7k in company stock

Published 04/02/2024, 09:33 PM
Updated 04/02/2024, 09:33 PM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) director Floyd F. Petersen has sold a portion of his holdings in the company, according to a recent Securities and Exchange Commission filing. On April 1, Petersen sold 500 shares of common stock at an average price of $43.4283 per share, totaling approximately $21,714.

The transactions were executed within a range of prices from $43.145 to $43.97, indicating a varied market performance on the day of the sale. Following this transaction, Petersen's remaining stake in the company consists of 79,333 shares of common stock.

Investors often monitor insider trading activity, such as sales and purchases of company stock, for insights into executives' confidence in their company's prospects. In this case, the sale was carried out under a pre-arranged trading plan, known as a Rule 10b5-1 plan, which Petersen had adopted on June 13, 2023. This type of plan allows company insiders to establish predetermined trading arrangements for selling stocks at a later date, providing a defense against potential accusations of trading on nonpublic information.

The sale by Petersen comes as part of his planned financial transactions and is not necessarily indicative of his view on the company's future performance. Amphastar Pharmaceuticals, a company operating in the pharmaceutical preparations industry, has not provided any additional comments regarding the transaction.

Investors and stakeholders in Amphastar Pharmaceuticals can request more detailed information about the sale, including the specific prices at which the shares were sold, if needed.

InvestingPro Insights

As Amphastar Pharmaceuticals (NASDAQ:AMPH) director Floyd F. Petersen's recent stock sale garners attention, insights from InvestingPro provide a broader context for investors evaluating the company's performance and prospects.

InvestingPro Tips highlight that management has been actively buying back shares, signaling confidence in the company's valuation and future. This is complemented by the fact that two analysts have revised their earnings upwards for the upcoming period, suggesting that there may be positive developments on the horizon for Amphastar Pharmaceuticals.

In terms of financial metrics, Amphastar Pharmaceuticals boasts a P/E Ratio (Adjusted) of 14.58 as of the last twelve months ending Q4 2023, which, when paired with a PEG Ratio of 0.3 during the same period, indicates that the stock may be trading at a low price relative to near-term earnings growth. Additionally, the company has demonstrated strong revenue growth of 29.14% over the last twelve months, illustrating its ability to expand effectively in the competitive pharmaceutical preparations industry.

These InvestingPro Tips and metrics are part of a larger suite of tools and analytics available on InvestingPro, which includes additional tips for investors looking to make informed decisions. For those interested in accessing the full range of insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 9 more InvestingPro Tips available for Amphastar Pharmaceuticals, providing a comprehensive analysis for investors and stakeholders.

The InvestingPro Tips and real-time data offer a valuable perspective on Amphastar Pharmaceuticals' financial health and market performance, which may help investors understand the broader context of insider trading activities such as Petersen's recent sale.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.